Article Text


Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis
  1. E. M. Veys,
  2. E. C. Huskisson,
  3. M. Rosenthal,
  4. T. L. Vischer,
  5. H. Mielants,
  6. P. A. Thrower,
  7. J. Scott,
  8. H. Ott,
  9. H. Scheijgrond,
  10. J. Symoens
  1. Department of Rheumatology, University of Ghent, Belgium
  2. Department of Rheumatology, St Bartholomew's Hospital, London
  3. Department of Rheumatology, Merian-Iselin-Spital, Basel, Switzerland
  4. Division of Rheumatology, University Department of Medicine, Hôpital Cantonal, Geneva, Switzerland
  5. Department of Rheumatology, University of Ghent, Belgium
  6. Department of Rheumatology, Hôpital La Chaux-de-Fonds, La Chaux-de-Fonds, Switzerland
  7. Department of Clinical Pharmacology, Janssen Pharmaceutica, Beerse, Belgium (co-ordination).


    The effect of thymopoietin pentapeptide (TP-5) was evaluated in patients with rheumatoid arthritis (RA). Ninety-two patients were divided into 3 groups, namely, placebo, TP-5 intramuscularly (IM) 1 mg, TP-5 intravenously (IV) 50 mg, and were evaluated for 6 measures of disease activity at the beginning of the study and at 3 and 6 months. No difference was observed between the placebo group and the group treated with TP-5 IM 1 mg. However, in the group treated with TP-5 IV 50 mg a statistically significant improvement of all parameters except the ESR was observed.

    Statistics from

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.